TheStreet's five interns discuss the biggest takeaways from Jim Cramer's monthly conference call with investors.
Trump has a clear agenda to prevent Germany from building up its second Nord Stream 2 gas pipeline. Here's why that matters.
Let's go over some of the news from Tuesday.
Untapped assets, consistent volume growth gives analyst optimistic outlook on Chevron
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
Paying for healthcare costs could be among your biggest concerns after retiring. Here's how the possible tie-in might change the way you access care.
RBC's Randall Stanicky says concerns have moved from being about global generic growth to Teva's branded drug business.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.